{
    "organizations": [],
    "uuid": "2a412a59f03522d14f9193db13b39c78a1656488",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-xbiotech-in-licenses-anti-ny-eso-1/brief-xbiotech-in-licenses-anti-ny-eso-1-antibody-targeting-advanced-cancer-idUSFWN1RF09I",
    "ord_in_thread": 0,
    "title": "BRIEF-XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - XBiotech Inc:\n* 1 MONOCLONAL ANTIBODY, 12D7 * HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-02T20:15:00.000+03:00",
    "crawled": "2018-04-03T15:59:00.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "xbiotech",
        "inc",
        "monoclonal",
        "antibody",
        "12d7",
        "obtained",
        "exclusive",
        "worldwide",
        "license",
        "ct",
        "atlantic",
        "ag",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}